Monday, November 2, 2026

@aleabitoreddit Oct 24 9 clicks

Serenity on X

$AMD was negotiating CW laser capacity LTAs from Trendforce. And are working with Ayar / $GFS for CPO deployments, (where $SIVE is upstream as the laser supplier/reference design) So there's strong overlap in photonics. However, AMD on Sivers website currently is likely baseband related from cellular + Xilinx.

@aleabitoreddit Oct 24

Serenity on X

I'll let this revenue projection graph I made for $AAOI do the talking. Price at $70 I find genuinely riduclous if they deliver on their projections. Rate hikes/macro trims a lot of forward valuations. But the selloff way overshot, which I'd argue is amplified by hedge fund risk/forced deleveraging before month end reporting. Rather than something individually wrong with the company.

@aleabitoreddit Oct 24

Serenity on X

Yes, I like $SIVE. It's a fun company to cover, since there's a lot of supply chain alpha here. But the company completely Tall Poppy Syndromed itself last earnings. And it's clearly shown in the drawdown. Bit of a longer consolidated thought and some scattered bits of supply chain info: - Sivers has 100M CW DFB laser capacity coming online Q4 2027 during an industry shortage. And very large allocations from foundries online (they were doing these quals with Win Semi + 2 others back in 2023/2024), so they can actively monetize the bottleneck today. The other interesting reason why bottlenecks are important (aside from ASP hikes), is because qualifications convert much faster + more likely given incentives around supply scarcity. -> As one example, module makers have expanded the amount of suppliers, eg. (lightcounting cited companies expanding to 5-7+ suppliers from 2-3). Innolight, for example last month responded to a question addressing tight 1.6T DFB laser supply in 2026–2027: - Innolight was actively introducing new suppliers last month and are planning to sign 2-3 year-long contracts to lock upstream capacity -> This is while your biggest merchant laser companies making up the world's 600m+ EML/CW laser capacity like $COHR have redirected lasers to their own programs. $LITE sold out into 2029, Landmark also locked a lot of their capacity into 2027-2029. $AAOI was an expected player, but ended up redirecting lasers into their own transceiver programs too. And this coincides with times $SIVE has tremendous capacity available now + actively engaged with Chinese pluggables players (not saying it's Innolight, but just shows Chinese makers like Cambridge/Eoptolink are actively trying to secure laser capacity). - Fun to note, before $JBL was announced, Sivers had and has ongoing direct engagements with hyperscalers as well. We saw that hyperscalers approached $MTSI and $AAOI for laser capacity from their earnings transcripts (and hilariously got turned away from AAOI due to shortages). So the odds pluggable makers or hyperscalers end up converting to capacity agreements with $SIVE seems a materially higher. Just a little rant: for all the sellside/retail trying to model revenue, you can't just slap on a stupid 25-35% CAGR on NRE revenue since it's close to 0 revenue now. Especially when they scale up to maybe 300M laser capacity (extrapolated from 2:1 external/internal capacity). It's also not the same as $POET having OE packaging capacity at scale, since lasers are in a genuine shortage. So capacity is more likely to convert like how $AAOI is sold out, $LITE is sold out into 2029 We've already seen what revenue that laser capacity brings in since $LITE cited $5B in laser capacity from just one 2028 fab alone in Greensboro (on higher end ranges). And whatever lasers Sivers sell, they're targeting ~50-60+ blended gross margins long term on maybe $3-6 for lower range lasers to $6-$12 for high end custom deployments. But no disclosures around capacity -> revenue conversion yet from Sivers. Now here's the thing people don't really understand, "why no revenue?" for current opportunities? $SIVE pre 2024 focused on custom development for future architectural shifts like CPO. For custom deployments: - We finally got conversion from 1 of their 4 or so lidar customers this week with ~ $AEVA. - ~ $APPL was confirmed ongoing earlier this year with an explanation that "It takes tremendous amount of trials and algorithms way beyond just what we supply to them". - All their customers from 2023-2024 like Ayar and 3 others, probably achieve volume in 2028 as CPO takes off. Custom high end lasers programs are extremely sticky but take many years and are mainly NRE. And as seen with CPO scale up, faced delays with commercialization over the years. So $SIVE from the CEO shift in 2024 realized "okay" let's ramp revenue with mass commercialization products today like 70mW/100mW/200mW lasers for 800g/1.6T pluggables. And that's where they found $JBL and all your other large pluggable players today during the shortage. Now... the work Sivers did in 2023-2024 earlier: Such as $AAPL, Ayar, $AEVA, other lidar/CPO players. And their new mass commercialization opportunities like $JBL, $GFS, and many pluggables/NPO suppliers in engagement now. Have all their inflection points converges 2027 onward, which is why I find the company compelling. Where I think management went completely wrong was messaging and near-term execution: - Deciding to focus on current tiny contracts like Seminex, AllSpace, Tachyon orders felt like the entire focus recently in earnings, shareholder letters, and media commentary -> Brutal honesty to $SIVE management, majority of Western audiences literally don't care and it's immaterial to the valuation. $SIVE moved 0% on all of the Seminex/AllSpace/Tachyon order announcements, and even dropped in price. But rallied like 50% on $GFS and something similar on $JBL announcement. The reason why most took long positions in the first place was CPO. So if $SIVE wants to go answer questions to Swedish media about "Why are you bleeding out" and defending that with cellular orders explaining pipeline conversion. That's not going to help people stay long during drawdowns. -> Second part was not committing to NASDAQ listing in a certain timeframe and actually executing. - If there's delays, sure, just say it, but non-committal lawyer-like language is infuriating to hear, especially from the CFO. I think they'll have that opportunity next month earnings to correct everything. So wrapping up: - There's nothing I see remotely close to $SIVE, in terms of % of global CW laser capacity they're coming online with relative to MC. - They have a ton commercialization paths, from O-Net, $POET, $JBL, Ayar, $GFS, $AAPL, $AEVA, and many potential hyperscaler/pluggable engagements. Even if one or two fall through, the breadth of ongoing quals is so deep + current laser bottleneck is severe, that it's more likely than not many will convert to production. It's clear $SIVE wants to focus on dominating the laser chokepoint first, and ended up using their 700m SEK fundraise for capacity expansion. But they should focus on communicating the billions in potential economic scale from that laser capacity conversion. And execute on it.

@TimyanBankAlert Oct 24 7 clicks

Timyan Bank Alert on X

First Citizens $FCNCA is open to buying more branches post-BMO deal https://t.co/87PPg7Wiuo

@StableBread Oct 23

Fajasy on X

Some notes on this post: 1) Not all of the $99.9M paid down lease debt. $BRUN's finance lease liabilities rose $207.7M on $268.3M of new finance leases, so the payments cut finance lease debt by only $60.6M. Most of the other $39.3M went to advance payments to secure new GPU leases ($37.5M in H1 2026, per the 10-Q's lease note), and the $39.7M of investing outflows paid for equipment and lease prepayments. So more than half of the $139.6M subtracted from operating cash flow was growth investment, while $BRUN added $337.3M of new GPU equipment in H1 2026. 2) The Cohere contract is also set up to be financed against. Cohere "acknowledges that Boost Run finances the equipment, facilities and working capital required to deliver the Services in part against this Agreement." $BRUN can assign its right to receive Cohere's fees to a financing party, and Cohere's obligation to pay undisputed fees is "absolute and unconditional." So $BRUN can borrow against Cohere's payments to pay for the racks, rather than funding them only from its own cash. 3) The material weaknesses behind the controls amendment weren't new. The amended Q1 10-Q says all three were "previously disclosed," including in $BRUN's S-4 (the merger filing). So the amendment corrected the original Q1 10-Q's "effective" conclusion to match weaknesses $BRUN had disclosed before the merger. 4) The CFO award's size dates to the merger, before the controls amendment. CFO Erik Guckel's May 8, 2026 employment agreement, signed when the merger closed, made him eligible for a one-time award covering 2,890,761 shares (time-based RSUs, performance-based RSUs, and options). The compensation committee's September 29, 2026 grant is 2,890,000 time-based RSUs.

@TidefallCapital Oct 23

Trevor Scott on X

$APP Past 5 year insider transactions: Sales: $15,825,097,564 Buys: $0 https://t.co/mIgIStK0yO

@StableBread Oct 23

Fajasy on X

@tailrisked And demand isn't what's holding $QMCO back. Backlog went from an $8-10M norm to $45M by March, then set another record in Q1, and Meyrath said IBM drive availability now caps growth, not orders. The LTO royalty also hit $2.3M in Q1, the highest in years. https://t.co/9Vt2Y1iZt0

@kevin__mak Oct 23 3 clicks

Kevin Mak on X

$ABVX Couple things I noted today. 1) The ABVX fans love to talk about how bad this specific stock is. But looking at a group of late-stage, pre-commercial biotech peers since August 20th, the weakness looks a lot less ABVX-specific. ABVX is down ~26%, versus a peer median of ~27%. Different stories and catalysts, but ABVX is right in the middle of the group. 2) The latest Markit securities-lending update shows a sharp drop in reported shares on loan, from ~2.6m to ~460k. My read is that this is consistent with the possible “large short” I previously flagged having covered. The drop shows up in the October 21 data, immediately after the October 20 +5.8% rally, which has since largely fizzled out. Disclosure: Creek Drive and its affiliated funds holds a long position in ABVX. Views expressed are current opinions for information only, subject to change and are not investment advice or a recommendation to buy or sell any security. Investing involves the risk of loss and past performance is not indicative of future performance. See the disclosures link in my bio for more important information.